Xenetic Biosciences plc, of London, said it completed the Phase I safety study of multiple sclerosis vaccine candidate MyeloXen on six healthy volunteers with no adverse events

Overall, the relative adverse event profiles were as anticipated for each therapy, including known events such as rash, diarrhea and hypomagnesemia

There were no serious adverse events

Thirty-two subjects completed the study, with no serious adverse events, dose-limiting safety findings or tolerability issues leading to withdrawal

No drug-related serious adverse events or dose-limiting toxicities were observed in either of the first two cohorts

No unexpected or serious adverse events were observed

Medgenics Inc., of San Francisco, said there have not been any procedure- or drug-related serious adverse events in the first four patients treated in the Phase IIa trial in Israel of Epodure biopumps for anemia in those on dialysis with end-stage renal disease

Adverse events were mild to moderate, with two severe events (infections) reported, which were determined to be unrelated to the study drug...There was a small number of mild adverse events, generally soreness associated with injection

The primary objectives include the evaluation of adverse events and a six-month clinical response...One patient suffered serious adverse events that led to discontinuation, but all other side effects were mild and transient

Both adult and pediatric patients demonstrated improvement, and adverse event rates were comparable between GMI-1070 and placebo

Through 74 weeks, eteplirsen was well tolerated and there were no clinically significant treatment-related adverse events, serious adverse events, hospitalizations or discontinuations

The drug was well tolerated, with similar rates of adverse events between the groups

No serious adverse events were reported, and the reported adverse events were mild to moderate and transient in nature

The primary objective of the study is to determine the maximum tolerated dose and recommend a Phase II dose for DBL0137 in those patients, while secondary objectives will include describing the dose-limiting toxicity, adverse event and pharmacokinetic profile, as well as documenting any objective responses...Data showed the drug was well tolerated throughout the study enrolling healthy volunteers, with no dose-limiting toxicities or serious adverse events observed

Omeros Corp., of Seattle, reported data from the multiple-ascending-dose portion of its Phase I trial, showing that OMS824, its lead phosphodiesterase 10 (PDE10) candidate, was well tolerated by all subjects, and the only apparent drug-related adverse event was mild somnolence at the highest dose evaluated

Treatment-related adverse events with CCH were mostly localized bruising, injection site pain and swelling, hematoma and musculoskeletal pain...Tedizolid was generally well tolerated, with gastrointestinal adverse events the most commonly reported emergent adverse events (16 percent in tedizolid vs. 20.5 percent in linezolid

The primary safety endpoints are dose-limiting adverse events, and primary efficacy endpoints are serum viral load reduction and degree of hepatocyte transduction, measured by liver biopsies

Pluristem Therapeutics Inc., of Haifa, Israel, said the first group of six patients has been dosed in its ongoing Phase I/II trial testing PLacental Expanded (PLX) cells in the treatment of muscle injury, without a significant adverse event related to either placebo or the PLX cell product candidate

No serious adverse events were reported